Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis

Long-Term Maintenance Therapy Using Rituximab-Induced Continuous B-Cell Depletion in Patients with ANCA Vasculitis

(2014) W. F. Pendergraft et al.   Clinical Journal of the American Society of Nephrology

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials

(2013) Joanna Robson et al.   ANNALS OF THE RHEUMATIC DISEASES

Decreased CD5+ B Cells in Active ANCA Vasculitis and Relapse after Rituximab

(2013) D. O. Bunch et al.   Clinical Journal of the American Society of Nephrology

Impact of rituximab trials on the treatment of ANCA-associated vasculitis

(2013) F. Alberici et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

(2013) Ulrich Specks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis

(2012) Alfred Mahr et al.   ANNALS OF THE RHEUMATIC DISEASES

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

(2012) A Ruyssen-Witrand et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center

(2012) Rodrigo Cartin-Ceba et al.   ARTHRITIS AND RHEUMATISM

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis

(2012) Rona M. Smith et al.   ARTHRITIS AND RHEUMATISM

Association Between −174 Interleukin-6 Gene Polymorphism and Biological Response to Rituximab in Several Systemic Autoimmune Diseases

(2012) Gema Robledo et al.   DNA AND CELL BIOLOGY

Genetically Distinct Subsets within ANCA-Associated Vasculitis

(2012) Paul A. Lyons et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis

(2011) Michael Walsh et al.   ARTHRITIS AND RHEUMATISM

A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis

(2011) K. Owczarczyk et al.   Science Translational Medicine

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis

(2008) O Flossmann et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of primary small and medium vessel vasculitis

(2008) C Mukhtyar et al.   ANNALS OF THE RHEUMATIC DISEASES

Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood

(2008) A. J. Ferraro et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis

(2008) Christian Pagnoux et al.   NEW ENGLAND JOURNAL OF MEDICINE